Anxiolytics Is Fastest Growing Segment Fueling The Growth Of Benzodiazepine Drugs Market
Anxiolytics Is Fastest Growing Segment Fueling The Growth Of Benzodiazepine Drugs Market
Benzodiazepine drugs are primarily prescribed to treat symptoms of anxiety, alcohol withdrawal, seizures, and muscle spasms.
Benzodiazepine drugs are primarily prescribed to treat symptoms of anxiety, alcohol withdrawal, seizures, and muscle spasms. They work by enhancing the effect of the GABA, a major inhibitory neurotransmitter in the central nervous system. They provide fast acting and effective relief from anxiety and insomnia.
 
 
The global Benzodiazepine Drugs Market is estimated to be valued at US$ 3148.01 Mn in 2023 and is expected to exhibit a CAGR of 3.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
 
Market key trends
 
One of the major trends in the benzodiazepine drugs market is the growing adoption of extended-release formulations. Long-acting benzodiazepines provide a consistent drug level in the blood for a longer period and reduce dosing frequency, leading to improved patient compliance. Companies are focusing on developing advanced drug delivery systems such as transdermal patches and sublingual tabs to provide extended release formulations. For instance, in 2018, Pascoe Pharma introduced Pascal XR tablets as a long-acting benzodiazepine formulation for the treatment of anxiety.
 
Segment Analysis
 
The global benzodiazepine drugs market can be segmented based on product type, application, distribution channel, and region. Based on product type, the diazepam segment dominated the global market in 2022 and is expected to continue its dominance over the forecast period. Diazepam is widely used for the treatment of anxiety disorder, alcohol withdrawal, muscle spasms, seizures, trouble sleeping, and restless leg syndrome. It is the most commonly prescribed benzodiazepine medication globally due to its long duration of action and relatively mild side effects.
 
Key Takeaways
 
The global Benzodiazepine Drugs Market Size was valued at US$ 3148.01 Mn in 2023 and is expected to exhibit a CAGR of 3.2% over the forecast period. Factors such as the rising geriatric population suffering from neurological disorders, the increasing prevalence of anxiety disorders, and the growing consumption of illicit benzodiazepine drugs are augmenting the market growth.
 
Regional analysis: North America dominated the global market in 2023 and is expected to continue its dominance over the forecast period. This is attributed to the developed healthcare infrastructure and higher diagnosis and treatment rates for anxiety and neurological disorders in the region.
 
Key players: Key players operating in the benzodiazepine drugs market are F.Hoffmann-La Roche Ltd., Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Pfizer Inc., Viatris Inc. (Mylan N.V.), Labiana Pharmaceuticals, Bausch Health Companies, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Par Pharmaceutical, and Intas Pharmaceuticals Ltd.
 
 

What's your reaction?

Comments

https://www.timessquarereporter.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!

Facebook Conversations